AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 OCT 7 - (NewsRx.com & NewsRx.net) -- Curis, Inc., (CRIS), a therapeutic drug-development company, announced that a recent journal article demonstrates that the Hedgehog signaling pathway is abnormally elevated in a series of human breast carcinoma tissue samples.
The report states that administration of a Hedgehog pathway inhibitor, cyclopamine, blocks the growth of the breast cancer cells that were isolated from those tumor tissues.
The report, entitled "Hedgehog Signaling Pathway is a New Therapeutic Target for Patients with Breast Cancer," is authored by researchers from the Graduate School of Medical Sciences at Kyushu University in Japan. Based on their results, the authors conclude that "the Hedgehog signaling pathway is constitutively activated in most breast carcinomas, and that the Hedgehog pathway is a potential therapeutic target for patients with breast cancer."
The report appeared in Cancer Research.
Daniel Passeri, Curis' president and CEO, said, ...
Source: HighBeam Research, Hedgehog signaling pathway is new therapeutic target for breast...